Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC payload

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (5) ADC Linker (14) ADC Payload (57) Drug-Linker Conjugates for ADC (44) Akt (1) Amino Acid Derivatives (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (24) Apoptosis (10) Bacterial (2) Biochemical Assay Reagents (1) Btk (1) c-Kit (1) c-Met/HGFR (2) Caspase (2) CD19 (1) CD22 (1) CD276/B7-H3 (1) DNA Alkylator/Crosslinker (12) DNA/RNA Synthesis (5) Drug Derivative (3) Drug Intermediate (1) EGFR (6) Epigenetic Reader Domain (1) ERK (1) Eukaryotic Initiation Factor (eIF) (3) Ferroptosis (1) FGFR (1) Folate Receptor (FR) (1) Glucocorticoid Receptor (2) Glutathione Peroxidase (1) IFNAR (1) Isotope-Labeled Compounds (2) Kinesin (1) Mesothelin (1) Microtubule/Tubulin (12) Mitosis (1) mTOR (1) Mucin (2) NAMPT (5) P-glycoprotein (1) PD-1/PD-L1 (1) PI3K (2) PROTAC Linkers (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (1) Ras (1) Reference Standards (2) STING (1) Toll-like Receptor (TLR) (3) Topoisomerase (17) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (141) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	ADC Synthesis (1) DBCO (2) Azide (1) Alkynes (1)

155

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Targets Recommended: ADC Payload ADC Antibody Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128952

Tesirine Maximum Cited Publications 7 Publications Verification SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-101161

SG3199 3 Publications Verification	DNA Alkylator/Crosslinker ADC Payload	Cancer
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .

HY-132162

7-MAD-MDCPT	ADC Payload	Cancer
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-101127

SGD-1882 PBD dimer	ADC Payload	Cancer
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

HY-129589

Thailanstatin A 2 Publications Verification	ADC Payload	Cancer
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC₅₀=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC₅₀s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-145399

AZ14170133 SG 3932; AZ-0133	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
AZ14170133 (SG 3932; AZ-0133) is a Drug-Linker Conjugates for ADC. AZ14170133 consists of the ADC cytotoxic payload topoisomerase 1 inhibitor and a linker. AZ14170133 can be used for synthesis of ADC AZD9592 (HY-171124) and AZD 8205 (HY-171689). AZ14170133 can be used for the research of cancer .

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	ADC Payload	Cancer
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-126663

N-Me-L-Ala-maytansinol	ADC Payload	Cancer
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate *(ADC)* .

HY-103688

N-Ac-γ-Calicheamicin-AcBut-NHS ester	ADC Payload	Cancer
AcBut-N-Ac-γ-Calicheamicin is an *ADC* cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA double-strand breaks. AcBut-N-Ac-γ-Calicheamicin is primarily used in the synthesis of antibody-drug conjugates (ADC) and holds promise for research in the field of cancer, including acute lymphoblastic leukemia (ALL) and other hematological malignancies .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-79490

Ac-Exatecan	ADC Payload Topoisomerase	Cancer
Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC₅₀ = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-171689

Puxitatug samrotecan AZD 8205; P-Sam	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR ⁺/HER2 ^- breast cancer .

HY-176415

Cys-MC-GGFG-Dxd	Drug-Linker Conjugates for ADC	Cancer
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable *ADC* drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .

HY-175203

Topi MF-6	Topoisomerase ADC Payload	Cancer
Topi MF-6 is a DNA topoisomerase I (Top1) inhibitor. Topi MF-6 can be used as an ADC payload .

HY-12460

SPDB-DM4 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .

HY-15581

MMAD Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10	Microtubule/Tubulin ADC Payload	Cancer
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).

HY-147408

Rezetecan SHR9265	Topoisomerase ADC Payload	Cancer
Rezetecan (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecan can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-154915

MC-EVCit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-144880

SC209 3-Aminophenyl Hemiasterlin	ADC Payload Microtubule/Tubulin P-glycoprotein	Cancer
SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for *ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC* molecules .

HY-176844

eIF4A-IN-1 intermediate	ADC Payload Drug Intermediate	Cancer
eIF4A-IN-1 intermediate (Compound 71E) is an intermediate of Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-1 intermediate can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .

HY-156756

7-Hydroxymethyl-10,11-MDCPT	ADC Payload	Cancer
7-Hydroxymethyl-10,11-MDCPT is a hydrophilic camptothecin analog. 7-Hydroxymethyl-10,11-MDCPT is a *payload* that can be used for ADC synthesis .

HY-42709

Z-Val-Ala-OH Carbobenzoxy-L-valyl-L-alanine	Amino Acid Derivatives	Cancer
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .

HY-177585

BCPT02 BLD1102	ADC Payload Topoisomerase	Cancer
BCPT02 (BLD1102) is a Topoisomerase-I inhibitor and ADC payload (ADC *Payload). BCPT02 can form the ADC* BCG041. BCPT02 is applicable to cancer-related research .

HY-148128

TAM470	Microtubule/Tubulin ADC Payload	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-176976

Exatecan-mpGNNG	Drug-Linker Conjugates for ADC	Cancer
Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .

HY-107502

Cryptophycin analog 1	ADC Payload	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .

HY-132162A

7-MAD-MDCPT hydrochloride	ADC Payload	Cancer
7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-164954

ADC Control Human IgG1-McMMAF	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).

HY-159774

ADC Control human IgG1-DM1	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .

HY-145078

PNU-EDA-Gly5	Drug-Linker Conjugates for ADC	Cancer
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5 .

HY-W190913

DBCO-PEG4-Val-Cit-PAB-PNP	ADC Linker	Cancer
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.

HY-147917

RNA polymerase II-IN-2	ADC Payload DNA/RNA Synthesis	Cancer
RNA polymerase II-IN-2 is a RNA polymerase II inhibitor with a K_i value of 74.1 nM. RNA polymerase II-IN-2 inhibits Pol II-mediated transcription and induces cytotoxicity in mammalian cells. RNA polymerase II-IN-2 serves as a payload for antibody-drug conjugates (ADC) and is applicable for cancer research .

HY-177285

NVP-BQS481	Kinesin ADC Payload	Cancer
NVP-BQS481 (Compound 1) is a selective Kinesin spindle protein-5 (Eg5) inhibitor with an IC₅₀< 0.5 nM. NVP-BQS481 has significant antimitotic and antitumor activity (IC₅₀: 0.0.9 nM for SK-OV-3ip cells). NVP-BQS481 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .

HY-102001

Tomaymycin DM	ADC Payload	Cancer
Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).

HY-176202

TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478) .

HY-171269

Anetumab-MMAE	ADC Antibody Mesothelin	Cancer
Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.

HY-171270

Clivatuzumab-MMAE	Antibody-Drug Conjugates (ADCs) Mucin	Cancer
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.

HY-156756S

7-Hydroxymethyl-10,11-MDCPT-d5	Isotope-Labeled Compounds ADC Payload	Others
7-Hydroxymethyl-10,11-MDCPT-d₅ is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for *ADC* synthesis .

HY-156249

NMS-P528	ADC Payload	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an **ADC payload**. NMS-P528 can be used to synthesize NMS-P945 .

HY-171081

Glucocorticoid receptor agonist-6	ADC Payload Glucocorticoid Receptor	Cancer
Glucocorticoid receptor agonist-6 (Compound A) is a Glucocorticoid receptor (GR) agonist. Glucocorticoid receptor agonist-6 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .

HY-176843

eIF4A-IN-2	Eukaryotic Initiation Factor (eIF) ADC Payload	Cancer
eIF4A-IN-2 (Compound 93) is an Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .

HY-164107

Auristatin S	ADC Payload Microtubule/Tubulin	Cancer
Auristatin S is an Auristatin payload with potent antitumor activity. Auristatin S attenuates bystander activity with improved off-target toxicity. Auristatin S has excellent tolerability in Karpas/KarpasBVR cell models. Auristatin S can be used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types .

HY-175004

PBD dimer-4	ADC Payload DNA Alkylator/Crosslinker	Cancer
PBD dimer-4 (Compound 7) is a C1-subsitituted PBD dimer. PBD dimer-4 has high DNA-binding affinity, DNA cross-linking ability and potent cytotoxicity against MDA-MB-231 cells (IC₅₀: 236 nM). PBD dimer-4 can be used as a payload of ADC Loncastuximab tesirine (HY-P99349) to treat several different cancer types .

HY-178270

PBD derivative-1	ADC Payload	Inflammation/Immunology Cancer
PBD derivative-1 (Compound 7-8) is a derivative of PBD, and PBD is the payload in antibody-drug conjugates (ADCs). PBD derivative-1 can be used for the synthesis of ADCs.

HY-135901

Py-MPB-amino-C3-PBD	ADC Payload Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-W1117786

Nampt-IN-10	ADC Payload NAMPT	Cancer
Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

116 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 116 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-177434

Precemtabart tocentecan

Precem-TcT; M 9140

Fluorescent Dye

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-170554

ABBV-706

Fluorescent Dye

ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors .

HY-177442

DS-3939a

DS-3939

Fluorescent Dye

DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .

HY-164729

FZ-AD005

Fluorescent Dye

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Fluorescent Dye
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-107502

Cryptophycin analog 1	Fluorescent Dye
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .

HY-P9994

Pertuzumab zuvotolimod

SBT6050

Fluorescent Dye

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-128952G

Tesirine

SG3249

Fluorescent Dye

Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-171191

REGN5093-M114	Fluorescent Dye
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .

Cat. No.	Product Name	Type

HY-128952G

Tesirine

SG3249

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-42709

Z-Val-Ala-OH Carbobenzoxy-L-valyl-L-alanine	Amino Acid Derivatives	Cancer
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting *ADC* comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P9994

Pertuzumab zuvotolimod SBT6050	Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P991906

TRPH-222 Antibody CD22-4AP Antibody; CAT-02-106 Antibody	ADC Antibody CD22	Cancer
TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .

HY-P991899

IKS03 Antibody LCB73 Antibody	ADC Antibody CD19	Cancer
IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Animals Classification of Application Fields Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Payload
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Chemical Structure

HY-156756S

7-Hydroxymethyl-10,11-MDCPT-d5
7-Hydroxymethyl-10,11-MDCPT-d₅ is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for *ADC* synthesis .

HY-101161S

SG3199-d6
SG3199-d₆ is the deuterium labeled SG3199 (HY-101161). SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249).

Cat. No.	Product Name		Classification

HY-147363

DIBAC-GGFG-NH2CH2-Dxd		DBCO ADC Synthesis
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-163099

P5(PEG24)-VC-PAB-Exatecan		Alkynes
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

HY-W190913

DBCO-PEG4-Val-Cit-PAB-PNP		DBCO
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.

HY-W800814

Azido-PEG8-Amido-Val-Cit-PAB		Azide
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.

Targets Recommended: ADC Payload ADC Antibody Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128952G

Tesirine SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ADC payload

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products